• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Colorectal Cancer - Pipeline Review, H1 2012 Product Image

Colorectal Cancer - Pipeline Review, H1 2012

  • Published: February 2012
  • 365 pages
  • Global Markets Direct

Colorectal Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Colorectal Cancer - Pipeline Review, H1 2012', provides an overview of the Colorectal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Colorectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colorectal Cancer. 'Colorectal Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Colorectal Cancer.
- A review of the Colorectal Cancer products under development by companies and universities/research institutes READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Colorectal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Colorectal Cancer
Colorectal Cancer Therapeutics under Development by Companies
Colorectal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Colorectal Cancer Therapeutics – Products under Development by Companies
Colorectal Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Colorectal Cancer Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Amgen Inc.
Sanofi-Aventis
Adherex Technologies Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Tekmira Pharmaceuticals Corp.
Genentech, Inc.
Nektar Therapeutics
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Oxford BioMedica plc
YM BioSciences Inc.
Labopharm Inc.
Symphogen A/S
Light Sciences Oncology, Inc.
Celltrion, Inc.
Novartis AG
Aphios Corporation
ImClone Systems Incorporated
Cephalon, Inc.
Chong Kun Dang Pharmaceutical
Chugai Pharmaceutical Co. Ltd
Eisai Co., Ltd.
Human Genome Sciences, Inc.
Nippon Kayaku Co., Ltd.
OSI Pharmaceuticals, Inc.
Pfizer Inc.
Taiho Pharmaceutical Co., Ltd.
Yakult Honsha Co., Ltd.
Enzon Pharmaceuticals, Inc.
Bayer AG
Merck KGaA
4SC AG
Neogenix Oncology Corporation
Alchemia Limited
EntreMed, Inc.
Celldex Therapeutics, Inc.
Enzo Biochem, Inc.
IMMUNOMEDICS, INC
InNexus Biotechnology Inc.
Neuren Pharmaceuticals Limited
Novogen Limited
Oncolytics Biotech Inc.
Oncothyreon Inc
Compugen Ltd.
Critical Outcome Technologies Inc.
Keryx Biopharmaceuticals, Inc.
ARQULE, INC
Telik, Inc.
Poniard Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Oncogenex Pharmaceuticals, Inc.
Dendreon Corporation
Transgene SA
Sirtex Medical Limited
Green Cross Corporation
MOLOGEN AG
Synta Pharmaceuticals Corp.
CrystalGenomics, Inc.
BioAlliance Pharma SA
NanoCarrier Co., Ltd.
Antisense Pharma GmbH
INSYS Therapeutics, Inc.
Philogen S.p.A.
Actis Biologics, Inc
Glycotope GmbH
immatics biotechnologies GmbH
Celator Pharmaceuticals, Inc.
MacroGenics, Inc.
ACT Biotech, Inc.
OncoMed Pharmaceuticals, Inc.
Boston Biomedical, Inc.
DanDrit Biotech A/S
Pivotal BioSciences, Inc.
Merrimack Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
Jennerex Biotherapeutics, Inc.
MolMed S.p.A.
PhytoCeutica, Inc.
Syndax Pharmaceuticals, Inc.
NOXXON Pharma AG
Globeimmune, Inc.
Etubics Corporation
CG Therapeutics, Inc.
Kinex Pharmaceuticals, LLC
CureTech Ltd.
Biothera
Nereus Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Dynamix Pharmaceuticals Ltd.
Isofol Medical AB
Cytavis Biopharma GmbH
Medical Enzymes AG
Prologue Research International, Inc.
Therapure Biopharma Inc.
VectorLogics, Inc.
ISA Pharmaceuticals B.V.
Oncozyme Pharma Inc.
Colorectal Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Perifosine - Drug Profile
Regorafenib - Drug Profile
HA-Irinotecan - Drug Profile
Eniluracil - Drug Profile
Angiozyme - Drug Profile
Avastin - Drug Profile
Afinitor - Drug Profile
IMC-1121B - Drug Profile
Davanat - Drug Profile
Vectibix - Drug Profile
Aptocine - Drug Profile
KRX-0401 + Xeloda - Drug Profile
MGN1703 - Drug Profile
Xeloda + Oxaliplatin - Drug Profile
FOLFOX + Vectibix - Drug Profile
MK-0646 + Cetuximab + Irinotecan - Drug Profile
Vectibix + FOLFIRI - Drug Profile
Recentin + FOLFOX - Drug Profile
Recentin + Xelox - Drug Profile
Eloxatin + Avastin + Leucovorin + Fluorouracil - Drug Profile
Eloxatin + Avastin + Capecitabine - Drug Profile
Fluorouracil + Leucovorin Calcium + CPT-11 - Drug Profile
CPT-11 + TS-1 - Drug Profile
Cetuximab + FOLFOX-4 - Drug Profile
Avastin + Irinotecan + Leucovorin + 5-Fluorouracil - Drug Profile
Imprime PGG + Erbitux - Drug Profile
Oxaliplatin + Leucovorin + 5-Fluorouracil - Drug Profile
Erbitux + FOLFIRI - Drug Profile
S-1 + Oxaliplatin + Bevacizumab - Drug Profile
S-1 + Oxaliplatin - Drug Profile
Tarceva - Drug Profile
Ramucirumab + FOLFIRI - Drug Profile
ZALTRAP + FOLFIRI - Drug Profile
Zaltrap - Drug Profile
FOLFIRI + Vectibix + Avastin - Drug Profile
FOLF(HA)Iri - Drug Profile
Aptocine + FOLFIRI - Drug Profile
Aptocine + FOLFOX4 - Drug Profile
Colorectal Cancer Therapeutics – Drug Profile Updates
Colorectal Cancer Therapeutics – Discontinued Products
Colorectal Cancer Therapeutics - Dormant Products
Colorectal Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Colorectal Cancer, H1 2012
Products under Development for Colorectal Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Development by Companies, H1 2012 (Contd..6)
Number of Products under Development by Companies, H1 2012 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..15)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..16)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..17)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Development by Companies, H1 2012 (Contd..9)
Products under Development by Companies, H1 2012 (Contd..10)
Products under Development by Companies, H1 2012 (Contd..11)
Products under Development by Companies, H1 2012 (Contd..12)
Products under Development by Companies, H1 2012 (Contd..13)
Products under Development by Companies, H1 2012 (Contd..14)
Products under Development by Companies, H1 2012 (Contd..15)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..26)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..27)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..28)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..29)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..30)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..31)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..32)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..33)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..34)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..35)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..36)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..37)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..38)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..39)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..40)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..41)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..42)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..43)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..44)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..45)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..46)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..47)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..48)
Bristol-Myers Squibb Company, H1 2012
Johnson & Johnson, H1 2012
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Abbott Laboratories, H1 2012
Amgen Inc., H1 2012
Sanofi-Aventis, H1 2012
Adherex Technologies Inc., H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
GlaxoSmithKline plc, H1 2012
Tekmira Pharmaceuticals Corp., H1 2012
Genentech, Inc., H1 2012
Nektar Therapeutics, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Merck & Co., Inc., H1 2012
Oxford BioMedica plc, H1 2012
YM BioSciences Inc., H1 2012
Labopharm Inc., H1 2012
Symphogen A/S, H1 2012
Light Sciences Oncology, Inc., H1 2012
Celltrion, Inc., H1 2012
Novartis AG, H1 2012
Aphios Corporation, H1 2012
ImClone Systems Incorporated, H1 2012
Cephalon, Inc., H1 2012
Chong Kun Dang Pharmaceutical, H1 2012
Chugai Pharmaceutical Co. Ltd, H1 2012
Eisai Co., Ltd., H1 2012
Human Genome Sciences, Inc., H1 2012
Nippon Kayaku Co., Ltd., H1 2012
OSI Pharmaceuticals, Inc., H1 2012
Pfizer Inc., H1 2012
Taiho Pharmaceutical Co., Ltd., H1 2012
Yakult Honsha Co., Ltd., H1 2012
Enzon Pharmaceuticals, Inc., H1 2012
Bayer AG, H1 2012
Merck KGaA, H1 2012
4SC AG, H1 2012
Neogenix Oncology Corporation, H1 2012
Alchemia Limited, H1 2012
EntreMed, Inc., H1 2012
Celldex Therapeutics, Inc., H1 2012
Enzo Biochem, Inc., H1 2012
IMMUNOMEDICS, INC, H1 2012
InNexus Biotechnology Inc., H1 2012
Neuren Pharmaceuticals Limited, H1 2012
Novogen Limited, H1 2012
Oncolytics Biotech Inc., H1 2012
Oncothyreon Inc, H1 2012
Compugen Ltd., H1 2012
Critical Outcome Technologies Inc., H1 2012
Keryx Biopharmaceuticals, Inc., H1 2012
ARQULE, INC, H1 2012
Telik, Inc., H1 2012
Poniard Pharmaceuticals, Inc., H1 2012
Regeneron Pharmaceuticals, Inc., H1 2012
Oncogenex Pharmaceuticals, Inc., H1 2012
Dendreon Corporation, H1 2012
Transgene SA, H1 2012
Sirtex Medical Limited, H1 2012
Green Cross Corporation, H1 2012
MOLOGEN AG, H1 2012
Synta Pharmaceuticals Corp., H1 2012
CrystalGenomics, Inc., H1 2012
BioAlliance Pharma SA, H1 2012
NanoCarrier Co., Ltd., H1 2012
Antisense Pharma GmbH, H1 2012
INSYS Therapeutics, Inc., H1 2012
Philogen S.p.A., H1 2012
Actis Biologics, Inc, H1 2012
Glycotope GmbH, H1 2012
immatics biotechnologies GmbH, H1 2012
Celator Pharmaceuticals, Inc., H1 2012
MacroGenics, Inc., H1 2012
ACT Biotech, Inc., H1 2012
OncoMed Pharmaceuticals, Inc., H1 2012
Boston Biomedical, Inc., H1 2012
DanDrit Biotech A/S, H1 2012
Pivotal BioSciences, Inc., H1 2012
Merrimack Pharmaceuticals, Inc., H1 2012
Deciphera Pharmaceuticals, LLC, H1 2012
Jennerex Biotherapeutics, Inc., H1 2012
MolMed S.p.A., H1 2012
PhytoCeutica, Inc., H1 2012
Syndax Pharmaceuticals, Inc., H1 2012
NOXXON Pharma AG, H1 2012
Globeimmune, Inc., H1 2012
Etubics Corporation, H1 2012
CG Therapeutics, Inc., H1 2012
Kinex Pharmaceuticals, LLC, H1 2012
CureTech Ltd., H1 2012
Biothera, H1 2012
Nereus Pharmaceuticals, Inc., H1 2012
AVEO Pharmaceuticals, Inc., H1 2012
Dynamix Pharmaceuticals Ltd., H1 2012
Isofol Medical AB, H1 2012
Cytavis Biopharma GmbH, H1 2012
Medical Enzymes AG, H1 2012
Prologue Research International, Inc., H1 2012
Therapure Biopharma Inc., H1 2012
VectorLogics, Inc., H1 2012
ISA Pharmaceuticals B.V., H1 2012
Oncozyme Pharma Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Colorectal Cancer Therapeutics – Drug Profile Updates
Colorectal Cancer Therapeutics – Discontinued Products
Colorectal Cancer Therapeutics – Discontinued Products (Contd..1)
Colorectal Cancer Therapeutics – Discontinued Products (Contd..2)
Colorectal Cancer Therapeutics – Discontinued Products (Contd..3)
Colorectal Cancer Therapeutics – Discontinued Products (Contd..4)
Colorectal Cancer Therapeutics – Discontinued Products (Contd..5)
Colorectal Cancer Therapeutics – Discontinued Products (Contd..6)
Colorectal Cancer Therapeutics – Dormant Products
Colorectal Cancer Therapeutics – Dormant Products (Contd..1)
Colorectal Cancer Therapeutics – Dormant Products (Contd..2)
Colorectal Cancer Therapeutics – Dormant Products (Contd..3)
Colorectal Cancer Therapeutics – Dormant Products (Contd..4)
Colorectal Cancer Therapeutics – Dormant Products (Contd..5)
Colorectal Cancer Therapeutics – Dormant Products (Contd..6)
Colorectal Cancer Therapeutics – Dormant Products (Contd..7)
Colorectal Cancer Therapeutics – Dormant Products (Contd..8)
Colorectal Cancer Therapeutics – Dormant Products (Contd..9)
Colorectal Cancer Therapeutics – Dormant Products (Contd..10)
Colorectal Cancer Therapeutics – Dormant Products (Contd..11)
Colorectal Cancer Therapeutics – Dormant Products (Contd..12)
Colorectal Cancer Therapeutics – Dormant Products (Contd..13)
Colorectal Cancer Therapeutics – Dormant Products (Contd..14)
Colorectal Cancer Therapeutics – Dormant Products (Contd..15)
Colorectal Cancer Therapeutics – Dormant Products (Contd..16)
Colorectal Cancer Therapeutics – Dormant Products (Contd..17)
Colorectal Cancer Therapeutics – Dormant Products (Contd..18)
Colorectal Cancer Therapeutics – Dormant Products (Contd..19)
Colorectal Cancer Therapeutics – Dormant Products (Contd..20)
Colorectal Cancer Therapeutics – Dormant Products (Contd..21)
Colorectal Cancer Therapeutics – Dormant Products (Contd..22)
Colorectal Cancer Therapeutics – Dormant Products (Contd..23)
Colorectal Cancer Therapeutics – Dormant Products (Contd..24)
Colorectal Cancer Therapeutics – Dormant Products (Contd..25)
Colorectal Cancer Therapeutics – Dormant Products (Contd..26)
Colorectal Cancer Therapeutics – Dormant Products (Contd..27)
Colorectal Cancer Therapeutics – Dormant Products (Contd..28)
Colorectal Cancer Therapeutics – Dormant Products (Contd..29)
Colorectal Cancer Therapeutics – Dormant Products (Contd..30)
Colorectal Cancer Therapeutics – Dormant Products (Contd..31)
Colorectal Cancer Therapeutics – Dormant Products (Contd..32)
Colorectal Cancer Therapeutics – Dormant Products (Contd..33)
Colorectal Cancer Therapeutics – Dormant Products (Contd..34)

List of Figures
Number of Products under Development for Colorectal Cancer, H1 2012
Products under Development for Colorectal Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos